JPRN-jRCTs051180041已完成未知
The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study) - ATOM-J Study
Kinoshita Shigeru0 个研究点目标入组 171 人开始时间: 2019年1月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 171
研究概览
简要总结
From the results of this study, it was shown that once-daily administration of 0.01% atropine eye drops safely and effectively suppresses the progression of myopia in Japanese school children, but long-term administration is required for the effect to appear. In the future, it will be necessary to examine the optimal concentration of atropine and whether 0.01% atropine concentration is appropriate even for patients with small pupils.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6age old 至 <= 12age old（—）
- 性别
- All
入选标准
- •(1) Male or female children aged 6 -to 12 years (elementary school grades 1-6) at the time of consent
- •(2) Children with a decrease in visual acuity in the vision assessment in a school physical examination within the past year.
- •(3) Children with a cycloplegic objective spherical equivalent of -1.00D to-6.00D in each eye
- •(4) Children with anisometropia within 1.50D.
- •(5) Children with astigmatism within +/- 1.50D
- •(6) Children with corrected visual acuity of at least 1.0
- •(7) Children with no intraocular pressure abnormalities
- •(8) Children capable of undergoing cycloplegia
- •(9) Children who can undergo outpatient examinations per protocol
- •(10) Written informed consent to participate in the study obtained from the child personally and from a person with parental authority
排除标准
- •(1) Children with abnormal visual function bilaterally
- •(2) Children with amblyopia or manifest strabismus
- •(3) Children with difference in objective spherical equivalent with and without cycloplegia of more than 1.00D in each eye
- •(4) Children with ocular disorders other than myopia
- •(5) Children with ocular or systemic disorders that potentially affect myopia or refractive power
- •(6) Children who have received previous treatment for myopia that included atropine therapy such as contact lenses, bifocal lenses, or progressive lenses with atropine therapy (however, this does not apply to children who discontinued 0.4% tropicamide ophthalmic solution at least 3 months previously)
- •(7) Children with a history of cardiovascular or respiratory disease
- •(8) Children who have received pharmacotherapy for asthma in the past year
- •(9) Children with a history of allergy to atropine, cyclopentolate, or benzalkonium
- •(10) Children who cannot instill medication into the eye
- •(11) Children who may require contact lenses, bifocal lenses, or progressive lenses during the clinical study period
- •(12) Children deemed otherwise unsuitable for the study by the (sub)investigator
研究者
相似试验
已完成
不适用
The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study)Mild or moderate myopiaJPRN-UMIN000018041Kyoto Prefectural University of Medicine180
招募中
不适用
Efficacy of 0.01% Atropine Ophthalmic Solution on Myopia Progression and Axial Elongation of the Eye in School Children with High- or Moderate-grade Myopiahigh- or moderate-grade myopiaJPRN-UMIN000028553Kawasaki Medical School Department of Ophthalmology 250
已完成
2 期
Effect of 0.01% atropine eye drops in children with moderate to high grade myopiarefractive error, development, childD009216MyopiaJPRN-jRCTs061180091Hasebe Satoshi18
尚未招募
4 期
Atropine eyedrops for treatment of increasing shortsightCTRI/2019/10/021538Dr Abraham Kurian
尚未招募
4 期
Atropine eyedrops for preventing increase in refractive error (shortsight and astigmatism)CTRI/2019/05/018970DrAbraham Kurian